Celularity

China-based Antengene Corporation Ltd (HKG: 6996) announced a preclinical partnership with U.S. firm Celularity Inc. to evaluate the combined potential of Antengene’s bispecific antibody (BsAb) and Celularity’s cryopreserved natural killer (NK) cell therapy derived from human placental hematopoietic stem cells. Financial terms were not disclosed. Collaboration DetailsThe partnership aims to…